Focus Partners Wealth Has $4.59 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Focus Partners Wealth increased its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 9.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,067 shares of the company's stock after acquiring an additional 5,760 shares during the period. Focus Partners Wealth's holdings in AstraZeneca were worth $4,589,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Moody National Bank Trust Division lifted its stake in AstraZeneca by 20.0% during the fourth quarter. Moody National Bank Trust Division now owns 4,556 shares of the company's stock valued at $299,000 after purchasing an additional 758 shares during the last quarter. Wallace Advisory Group LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at $171,000. Accurate Wealth Management LLC lifted its position in shares of AstraZeneca by 3.4% during the 4th quarter. Accurate Wealth Management LLC now owns 8,463 shares of the company's stock valued at $567,000 after acquiring an additional 275 shares during the last quarter. Pines Wealth Management LLC bought a new stake in shares of AstraZeneca during the 4th quarter worth $378,000. Finally, Community Trust & Investment Co. grew its holdings in shares of AstraZeneca by 5.1% in the 4th quarter. Community Trust & Investment Co. now owns 183,523 shares of the company's stock worth $12,024,000 after acquiring an additional 8,903 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN traded down $0.03 during midday trading on Tuesday, hitting $69.66. The company's stock had a trading volume of 1,630,618 shares, compared to its average volume of 5,172,767. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The stock's 50 day simple moving average is $70.35 and its 200 day simple moving average is $69.43. The stock has a market capitalization of $216.04 billion, a price-to-earnings ratio of 30.79, a PEG ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same period in the previous year, the company earned $2.06 earnings per share. The company's quarterly revenue was up 7.2% compared to the same quarter last year. As a group, research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. Morgan Stanley started coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They set an "overweight" rating for the company. Finally, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.